Inventera is a biotech company, founded in 2018, specializing in the development of cutting-edge MRI contrast agents. Our core strength lies in our nanoparticle-based platforms, designed to enhance both the resolution and safety of MRI. By utilizing biocompatible iron (Fe) instead of gadolinium (Gd), which has raised significant safety concerns, our technology enables precise diagnosis for conditions that are challenging to address with existing contrast agents.

​

Building on this core technology, our pipeline is focused on addressing high-demand, critical indications that remain difficult to diagnose with current MRI contrast agents. Specifically, we are developing advanced contrast agents targeting the articular system, lymphatic vessels, and the pancreatic and biliary systems.

​

Our MR Arthrography (MRA) contrast agent candidate, INV-002, demonstrated both safety and efficacy in a Phase 1/2a clinical trial in Korea in 2023. It is currently undergoing a Phase 2b clinical trial in Korea, with preparations underway for a Phase 2b trial in the United States.

​

Similarly, our MR Lymphangiography (MRL) contrast agent candidate, INV-001, received IND approval for a Phase 1/2a clinical trial in Korea in November 2023, with completion of the trial expected by 2025.

 

Inventera’s high-performance contrast agents are designed to meet unmet medical needs and provide technically advanced solutions. Rather than competing within the existing market, we aim to expand and redefine it with our differentiated efficacy and focus on breakthrough indications. Our goal is to enhance diagnostic accuracy and patient safety, driving the rapid launch of our products, and ultimately realizing our vision of becoming a comprehensive imaging solutions company.